Gentium Submit 2nd LoOIs Response to the EMA's CHMP for Defibrotide MAA

Gentium S.p.A. Nasdaq:GENT) today announced that it has submitted responses to the second List of Outstanding Issues to the European Medicines Agency's Committee for Medicinal Products for Human Use in connection with the Company's Marketing Authorization Application for Defibrotide to treat and prevent hepatic veno-occlusive disease in adults and ... (more)

http://www.drugs.com/clinical_trials/gentium-submit-2nd-loois-response-ema-s-chmp-defibrotide-maa-14947.html?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+Drugscom-ClinicalTrials+%28Drugs.com+-+Clinical+Trials%29